Gastric cancer stem cells: evidence, potential markers, and clinical implications
详细信息 查看全文
- 作者：Daniel Brungs ; Morteza Aghmesheh ; Kara L. Vine…
- 关键词：Stomach neoplasms ; Gastric cancer ; Cancer stem cells ; CD44 ; CD44v ; CD133 ; ALDH1
- 刊名：Journal of Gastroenterology
- 出版年：2016
- 出版时间：April 2016
- 年：2016
- 卷：51
- 期：4
- 页码：313-326
- 全文大小：589 KB
- 参考文献：1.Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.PubMed CrossRef
2.Vermeulen L, de Sousa e Melo F, Richel DJ, et al. The developing cancer stem-cell model: clinical challenges and opportunities. Lancet Oncol. 2012;13(2):e83–9.PubMed CrossRef
3.Dewi DL, Ishii H, Kano Y, et al. Cancer stem cell theory in gastrointestinal malignancies: recent progress and upcoming challenges. J Gastroenterol. 2011;46(10):1145–57.PubMed CrossRef
4.Ding L, Raphael BJ, Chen F, et al. Advances for studying clonal evolution in cancer. Cancer Lett. 2013;340(2):212–9.PubMed CrossRef
5.O’Connor ML, Xiang D, Shigdar S, et al. Cancer stem cells: a contentious hypothesis now moving forward. Cancer Lett. 2014;344(2):180–7.PubMed CrossRef
6.Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem cells. Nature. 2001;414(6859):105–11.PubMed CrossRef
7.Vermeulen L, De Sousa EMF, van der Heijden M, et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol. 2010;12(5):468–76.PubMed CrossRef
8.Liu S, Ginestier C, Ou SJ, et al. Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res. 2011;71(2):614–24.PubMed PubMedCentral CrossRef
9.Notta F, Mullighan CG, Wang JC, et al. Evolution of human BCRABL1 lymphoblastic leukaemia-initiating cells. Nature. 2011;469(7330):362–7.PubMed CrossRef
10.Shackleton M, Quintana E, Fearon ER, et al. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell. 2009;138(5):822–9.PubMed CrossRef
11.Takaishi S, Okumura T, Tu S, et al. Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells. 2009;27(5):1006–20.PubMed PubMedCentral CrossRef
12.Liu J, Ma L, Xu J, et al. Spheroid body-forming cells in the human gastric cancer cell line MKN-45 possess cancer stem cell properties. Int J Oncol. 2013;42(2):453–9.PubMed PubMedCentral
13.Xu G, Shen J, Ou Yang X, et al. Cancer stem cells: the ‘heartbeat’ of gastric cancer. J Gastroenterol. 2013;48(7):781–97.PubMed CrossRef
14.Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3(7):730–7.PubMed CrossRef
15.Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. PNAS. 2003;100(7):3983–8.PubMed PubMedCentral CrossRef
16.Collins AT, Berry PA, Hyde C, et al. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005;65(23):10946–51.PubMed CrossRef
17.Hermann PC, Huber SL, Herrler T, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 2007;1(3):313–23.PubMed CrossRef
18.Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Res. 2007;67(3):1030–7.PubMed CrossRef
19.Fang D, Nguyen TK, Leishear K, et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res. 2005;65(20):9328–37.PubMed CrossRef
20.O’Brien CA, Pollett A, Gallinger S, et al. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007;445(7123):106–10.PubMed CrossRef
21.Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007;445(7123):111–5.PubMed CrossRef
22.Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature. 2004;432(7015):396–401.PubMed CrossRef
23.Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003;63(18):5821–8.PubMed
24.Ma S, Chan KW, Hu L, et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology. 2007;132(7):2542–56.PubMed CrossRef
25.Chen J, Li Y, Yu TS, et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature. 2012;488(7412):522–6.PubMed PubMedCentral CrossRef
26.Clarke MF, Dick JE, Dirks PB, et al. Cancer stem cells–perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 2006;66(19):9339–44.PubMed CrossRef
27.Takaishi S, Okumura T, Wang TC. Gastric cancer stem cells. J Clin Oncol. 2008;26(17):2876–82.PubMed PubMedCentral CrossRef
28.Sampieri K, Fodde R. Cancer stem cells and metastasis. Sem Can Biol. 2012;22(3):187–93.CrossRef
29.Pang R, Law WL, Chu AC, et al. A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer. Cell Stem Cell. 2010;6(6):603–15.PubMed CrossRef
30.Croker AK, Goodale D, Chu J, et al. High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. J Cell Mol Med. 2009;13(8b):2236–52.PubMed CrossRef
31.Dieter SM, Ball CR, Hoffmann CM, et al. Distinct types of tumor-initiating cells form human colon cancer tumors and metastases. Cell Stem Cell. 2011;9(4):357–65.PubMed CrossRef
32.Mayer B, Jauch KW, Gunthert U, et al. De-novo expression of CD44 and survival in gastric cancer. Lancet. 1993;342(8878):1019–22.PubMed CrossRef
33.Chen S, Hou JH, Feng XY, et al. Clinicopathologic significance of putative stem cell marker, CD44 and CD133, in human gastric carcinoma. J Surg Oncol. 2013;107(8):799–806.PubMed CrossRef
34.Meng F, Wu G. The rejuvenated scenario of epithelial-mesenchymal transition (EMT) and cancer metastasis. Cancer Metastasis Rev. 2012;31(3–4):455–67.PubMed CrossRef
35.Gupta PB, Chaffer CL, Weinberg RA. Cancer stem cells: mirage or reality? Nat Med. 2009;15(9):1010–2.PubMed CrossRef
36.Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133(4):704–15.PubMed PubMedCentral CrossRef
37.Morel AP, Lievre M, Thomas C, et al. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One. 2008;3(8):e2888.PubMed PubMedCentral CrossRef
38.Tinhofer I, Saki M, Niehr F, et al. Cancer stem cell characteristics of circulating tumor cells. Int J Radiat Biol. 2014;90(8):622–7.PubMed CrossRef
39.Li M, Zhang B, Zhang Z, et al. Stem cell-like circulating tumor cells indicate poor prognosis in gastric cancer. BioMed Res Int. 2014;2014:981261.PubMed PubMedCentral
40.Ryu HS, do Park J, Kim HH, et al. Combination of epithelial-mesenchymal transition and cancer stem cell-like phenotypes has independent prognostic value in gastric cancer. Hum Pathol. 2012;43(4):520–8.PubMed CrossRef
41.Xue Z, Yan H, Li J, et al. Identification of cancer stem cells in vincristine preconditioned SGC7901 gastric cancer cell line. J Cell Biochem. 2012;113(1):302–12.PubMed CrossRef
42.Kelly PN, Dakic A, Adams JM, et al. Tumor growth need not be driven by rare cancer stem cells. Science. 2007;317(5836):337.PubMed CrossRef
43.Marx J. Molecular biology. Cancer’s perpetual source? Science. 2007;317(5841):1029–31.PubMed CrossRef
44.Yang L, Ping YF, Yu X, et al. Gastric cancer stem-like cells possess higher capability of invasion and metastasis in association with a mesenchymal transition phenotype. Cancer Lett. 2011;310(1):46–52.PubMed
45.Zhou S, Schuetz JD, Bunting KD, et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med. 2001;7(9):1028–34.PubMed CrossRef
46.Golebiewska A, Brons NH, Bjerkvig R, et al. Critical appraisal of the side population assay in stem cell and cancer stem cell research. Cell Stem Cell. 2011;8(2):136–47.PubMed CrossRef
47.Zhang H, Xi H, Cai A, et al. Not all side population cells contain cancer stem-like cells in human gastric cancer cell lines. Dig Dis Sci. 2013;58(1):132–9.PubMed CrossRef
48.Nishii T, Yashiro M, Shinto O, et al. Cancer stem cell-like SP cells have a high adhesion ability to the peritoneum in gastric carcinoma. Cancer Sci. 2009;100(8):1397–402.PubMed CrossRef
49.Fukuda K, Saikawa Y, Ohashi M, et al. Tumor initiating potential of side population cells in human gastric cancer. Int J Oncol. 2009;34(5):1201–7.PubMed
50.She JJ, Zhang PG, Wang X, et al. Side population cells isolated from KATO III human gastric cancer cell line have cancer stem cell-like characteristics. World J Gastroenterol. 2012;18(33):4610–7.PubMed PubMedCentral CrossRef
51.Burkert J, Otto WR, Wright NA. Side populations of gastrointestinal cancers are not enriched in stem cells. J Pathol. 2008;214(5):564–73.PubMed CrossRef
52.Bjerknes M, Cheng H. Multipotential stem cells in adult mouse gastric epithelium. Am J Physiol Gastrointest Liver Physiol. 2002;283(3):G767–77.PubMed CrossRef
53.Wu C, Xie Y, Gao F, et al. Lgr5 expression as stem cell marker in human gastric gland and its relatedness with other putative cancer stem cell markers. Gene. 2013;525(1):18–25.PubMed CrossRef
54.Barker N, Huch M, Kujala P, et al. Lgr5(+ve) stem cells drive self-renewal in the stomach and build long-lived gastric units in vitro. Cell Stem Cell. 2010;6(1):25–36.PubMed CrossRef
55.Qiao XT, Ziel JW, McKimpson W, et al. Prospective identification of a multilineage progenitor in murine stomach epithelium. Gastroenterology. 2007;133(6):1989–98.PubMed PubMedCentral CrossRef
56.Arnold K, Sarkar A, Yram MA, et al. Sox2(+) adult stem and progenitor cells are important for tissue regeneration and survival of mice. Cell Stem Cell. 2011;9(4):317–29.PubMed PubMedCentral CrossRef
57.Stange DE, Koo BK, Huch M, et al. Differentiated Troy+ chief cells act as reserve stem cells to generate all lineages of the stomach epithelium. Cell. 2013;155(2):357–68.PubMed PubMedCentral CrossRef
58.Wang S, Tie J, Wang R, et al. SOX2, a predictor of survival in gastric cancer, inhibits cell proliferation and metastasis by regulating PTEN. Cancer Lett. 2015;358(2):210–9.PubMed CrossRef
59.Li XL, Eishi Y, Bai YQ, et al. Expression of the SRY-related HMG box protein SOX2 in human gastric carcinoma. Int J Oncol. 2004;24(2):257–63.PubMed
60.Matsuoka J, Yashiro M, Sakurai K, et al. Role of the stemness factors sox2, oct3/4, and nanog in gastric carcinoma. J Surg Res. 2012;174(1):130–5.PubMed CrossRef
61.Hutz K, Mejias-Luque R, Farsakova K, et al. The stem cell factor SOX2 regulates the tumorigenic potential in human gastric cancer cells. Carcinogenesis. 2014;35(4):942–50.PubMed CrossRef
62.Otsubo T, Akiyama Y, Yanagihara K, et al. SOX2 is frequently downregulated in gastric cancers and inhibits cell growth through cell-cycle arrest and apoptosis. Br J Cancer. 2008;98(4):824–31.PubMed PubMedCentral CrossRef
63.Giannakis M, Stappenbeck TS, Mills JC, et al. Molecular properties of adult mouse gastric and intestinal epithelial progenitors in their niches. J Biol Chem. 2006;281(16):11292–300.PubMed CrossRef
64.Okumura T, Ericksen RE, Takaishi S, et al. K-ras mutation targeted to gastric tissue progenitor cells results in chronic inflammation, an altered microenvironment, and progression to intraepithelial neoplasia. Cancer Res. 2010;70(21):8435–45.PubMed PubMedCentral CrossRef
65.Bessede E, Staedel C, Acuna Amador LA, et al. Helicobacter pylori generates cells with cancer stem cell properties via epithelial-mesenchymal transition-like changes. Oncogene. 2014;33(32):4123–31.PubMed CrossRef
66.Houghton J, Stoicov C, Nomura S, et al. Gastric cancer originating from bone marrow-derived cells. Science. 2004;306(5701):1568–71.PubMed CrossRef
67.Okumura T, Wang SS, Takaishi S, et al. Identification of a bone marrow-derived mesenchymal progenitor cell subset that can contribute to the gastric epithelium. Lab Invest. 2009;89(12):1410–22.PubMed PubMedCentral CrossRef
68.Varon C, Dubus P, Mazurier F, et al. Helicobacter pylori infection recruits bone marrow-derived cells that participate in gastric preneoplasia in mice. Gastroenterology. 2012;142(2):281–91.PubMed CrossRef
69.Bessede E, Dubus P, Megraud F, et al. Helicobacter pylori infection and stem cells at the origin of gastric cancer. Oncogene. 2015;34(20):2547–55.PubMed CrossRef
70.Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol. 2003;4(1):33–45.PubMed CrossRef
71.Olsson E, Honeth G, Bendahl PO, et al. CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers. BMC Cancer. 2011;11:418.PubMed PubMedCentral CrossRef
72.Ishimoto T, Nagano O, Yae T, et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(−) and thereby promotes tumor growth. Cancer Cell. 2011;19(3):387–400.PubMed CrossRef
73.Rocco A, Liguori E, Pirozzi G, et al. CD133 and CD44 cell surface markers do not identify cancer stem cells in primary human gastric tumors. J Cell Physiol. 2012;227(6):2686–93.PubMed CrossRef
74.Fukamachi H, Seol HS, Shimada S, et al. CD49f(high) cells retain sphere-forming and tumor-initiating activities in human gastric tumors. PLoS One. 2013;8(8):e72438.PubMed PubMedCentral CrossRef
75.Han ME, Jeon TY, Hwang SH, et al. Cancer spheres from gastric cancer patients provide an ideal model system for cancer stem cell research. Cell Mol Life Sci. 2011;68(21):3589–605.PubMed CrossRef
76.Lau WM, Teng E, Chong HS, et al. CD44v8-10 is a cancer-specific marker for gastric cancer stem cells. Cancer Res. 2014;74(9):2630–41.PubMed CrossRef
77.Chen T, Yang K, Yu J, et al. Identification and expansion of cancer stem cells in tumor tissues and peripheral blood derived from gastric adenocarcinoma patients. Cell Res. 2012;22(1):248–58.PubMed PubMedCentral CrossRef
78.Zhang C, Li C, He F, et al. Identification of CD44+ CD24+ gastric cancer stem cells. J Cancer Res Clin. 2011;137(11):1679–86.CrossRef
79.Yin AH, Miraglia S, Zanjani ED, et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood. 1997;90(12):5002–12.PubMed
80.Mizrak D, Brittan M, Alison M. CD133: molecule of the moment. J Pathol. 2008;214(1):3–9.PubMed CrossRef
81.Irollo E, Pirozzi G. CD133: to be or not to be, is this the real question? Am J Transl Res. 2013;5(6):563–81.PubMed PubMedCentral
82.Kemper K, Sprick MR, de Bree M, et al. The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation. Cancer Res. 2010;70(2):719–29.PubMed CrossRef
83.Wakamatsu Y, Sakamoto N, Oo HZ, et al. Expression of cancer stem cell markers ALDH1, CD44 and CD133 in primary tumor and lymph node metastasis of gastric cancer. Pathol Int. 2012;62(2):112–9.PubMed CrossRef
84.Muzio G, Maggiora M, Paiuzzi E, et al. Aldehyde dehydrogenases and cell proliferation. Free Radic Biol Med. 2012;52(4):735–46.PubMed CrossRef
85.Nishikawa S, Konno M, Hamabe A, et al. Aldehyde dehydrogenase high gastric cancer stem cells are resistant to chemotherapy. Int J Oncol. 2013;42(4):1437–42.PubMed
86.Katsuno Y, Ehata S, Yashiro M, et al. Coordinated expression of REG4 and aldehyde dehydrogenase 1 regulating tumourigenic capacity of diffuse-type gastric carcinoma-initiating cells is inhibited by TGF-beta. J Pathol. 2012;228(3):391–404.PubMed CrossRef
87.Fujikuni N, Yamamoto H, Tanabe K, et al. Hypoxia-mediated CD24 expression is correlated with gastric cancer aggressiveness by promoting cell migration and invasion. Cancer Sci. 2014;105(11):1411–20.PubMed PubMedCentral CrossRef
88.Chou YY, Jeng YM, Lee TT, et al. Cytoplasmic CD24 expression is a novel prognostic factor in diffuse-type gastric adenocarcinoma. Ann Surg Oncol. 2007;14(10):2748–58.PubMed CrossRef
89.Imano M, Itoh T, Satou T, et al. High expression of epithelial cellular adhesion molecule in peritoneal metastasis of gastric cancer. Target Oncol. 2013;8(4):231–5.PubMed CrossRef
90.Wenqi D, Li W, Shanshan C, et al. EpCAM is overexpressed in gastric cancer and its downregulation suppresses proliferation of gastric cancer. J Cancer Res Clin Oncol. 2009;135(9):1277–85.PubMed CrossRef
91.Schildberg FA, Wojtalla A, Siegmund SV, et al. Murine hepatic stellate cells veto CD8 T cell activation by a CD54-dependent mechanism. Hepatology. 2011;54(1):262–72.PubMed CrossRef
92.Yashiro M, Sunami T, Hirakawa K. CD54 expression is predictive for lymphatic spread in human gastric carcinoma. Dig Dis Sci. 2005;50(12):2224–30.PubMed CrossRef
93.Jiang J, Zhang Y, Chuai S, et al. Trastuzumab (herceptin) targets gastric cancer stem cells characterized by CD90 phenotype. Oncogene. 2012;31(6):671–82.PubMed CrossRef
94.Ohkuma M, Haraguchi N, Ishii H, et al. Absence of CD71 transferrin receptor characterizes human gastric adenosquamous carcinoma stem cells. Ann Surg Oncol. 2012;19(4):1357–64.PubMed CrossRef
95.Lin S, Qi W, Han K, et al. Prognostic value of SOX2 in digestive tumors: a meta-analysis. Hepatol Gastroenterol. 2014;61(133):1274–8.
96.Li N, Deng W, Ma J, et al. Prognostic evaluation of Nanog, Oct4, Sox2, PCNA, Ki67 and E-cadherin expression in gastric cancer. Med Oncol. 2015;32(1):433.PubMed CrossRef
97.Kong D, Su G, Zha L, et al. Coexpression of HMGA2 and Oct4 predicts an unfavorable prognosis in human gastric cancer. Med Oncol. 2014;31(8):130.PubMed CrossRef
98.Wang T, Ong CW, Shi J, et al. Sequential expression of putative stem cell markers in gastric carcinogenesis. Br J Cancer. 2011;105(5):658–65.PubMed PubMedCentral CrossRef
99.Wang W, Dong LP, Zhang N, et al. Role of cancer stem cell marker CD44 in gastric cancer: a meta-analysis. Int J Clin Exp Med. 2014;7(12):5059–66.PubMed PubMedCentral
100.Liu YJ, Yan PS, Li J, et al. Expression and significance of CD44 s, CD44v6, and nm23 mRNA in human cancer. World J Gastroenterol. 2005;11(42):6601–6.PubMed PubMedCentral CrossRef
101.Kim JY, Bae BN, Kim KS, et al. Osteopontin, CD44, and NFkappaB expression in gastric adenocarcinoma. Cancer Res Treat. 2009;41(1):29–35.PubMed PubMedCentral CrossRef
102.Wen L, Chen XZ, Yang K, et al. Prognostic value of cancer stem cell marker CD133 expression in gastric cancer: a systematic review. PLoS One. 2013;8(3):e59154.PubMed PubMedCentral CrossRef
103.Xia P, Song CL, Liu JF, et al. Prognostic value of circulating CD133(+) cells in patients with gastric cancer. Cell Prolif. 2015;48(3):311–7.PubMed CrossRef
104.Yoon C, do Park J, Schmidt B, et al. CD44 expression denotes a subpopulation of gastric cancer cells in which Hedgehog signaling promotes chemotherapy resistance. Clin Cancer Res. 2014;20(15):3974–88.PubMed PubMedCentral CrossRef
105.Xu ZY, Tang JN, Xie HX, et al. 5-Fluorouracil chemotherapy of gastric cancer generates residual cells with properties of cancer stem cells. Int J Biol Sci. 2015;11(3):284–94.PubMed PubMedCentral CrossRef
106.Du YR, Chen Y, Gao Y, et al. Effects and mechanisms of anti-CD44 monoclonal antibody A3D8 on proliferation and apoptosis of sphere-forming cells with stemness from human ovarian cancer. Int J Gynecol Cancer. 2013;23(8):1367–75.PubMed CrossRef
107.Alshaer W, Hillaireau H, Vergnaud J, et al. Functionalizing liposomes with anti-CD44 Aptamer for selective targeting of cancer cells. Bioconjug Chem. 2015;26(7):1307–13.PubMed CrossRef
108.Wang L, Su W, Liu Z, et al. CD44 antibody-targeted liposomal nanoparticles for molecular imaging and therapy of hepatocellular carcinoma. Biomaterials. 2012;33(20):5107–14.PubMed CrossRef
109.Noh I, Kim HO, Choi J, et al. Co-delivery of paclitaxel and gemcitabine via CD44-targeting nanocarriers as a prodrug with synergistic antitumor activity against human biliary cancer. Biomaterials. 2015;53:763–74.PubMed CrossRef
110.Yao HJ, Zhang YG, Sun L, et al. The effect of hyaluronic acid functionalized carbon nanotubes loaded with salinomycin on gastric cancer stem cells. Biomaterials. 2014;35(33):9208–23.PubMed CrossRef
111.Serafino A, Zonfrillo M, Andreola F, et al. CD44-targeting for antitumor drug delivery: a new SN-38-hyaluronan bioconjugate for locoregional treatment of peritoneal carcinomatosis. Curr Cancer Drug Targets. 2011;11(5):572–85.PubMed CrossRef
112.Tanaka Y, Makiyama Y, Mitsui Y. Anti-CD44 monoclonal antibody (IM7) induces murine systemic shock mediated by platelet activating factor. J Autoimmun. 2002;18(1):9–15.PubMed CrossRef
113.Vugts DJ, Heuveling DA, Stigter-van Walsum M, et al. Preclinical evaluation of 89Zr-labeled anti-CD44 monoclonal antibody RG7356 in mice and cynomolgus monkeys: prelude to Phase 1 clinical studies. MAbs. 2014;6(2):567–75.PubMed PubMedCentral CrossRef
114.Swaminathan SK, Roger E, Toti U, et al. CD133-targeted paclitaxel delivery inhibits local tumor recurrence in a mouse model of breast cancer. J Control Rel. 2013;171(3):280–7.CrossRef
115.Skubitz AP, Taras EP, Boylan KL, et al. Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression. Gynecol Oncol. 2013;130(3):579–87.PubMed PubMedCentral CrossRef
116.Smith LM, Nesterova A, Ryan MC, et al. CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. Br J Cancer. 2008;99(1):100–9.PubMed PubMedCentral CrossRef
117.Ammons WS, Bauer RJ, Horwitz AH, et al. In vitro and in vivo pharmacology and pharmacokinetics of a human engineered monoclonal antibody to epithelial cell adhesion molecule. Neoplasia. 2003;5(2):146–54.PubMed PubMedCentral CrossRef
118.Schmidt M, Ruttinger D, Sebastian M, et al. Phase IB study of the EpCAM antibody adecatumumab combined with docetaxel in patients with EpCAM-positive relapsed or refractory advanced-stage breast cancer. Ann Oncol. 2012;23(9):2306–13.PubMed CrossRef
119.Paik S, Kim C, Wolmark N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med. 2008;358(13):1409–11.PubMed CrossRef
120.Wu WK, Cho CH, Lee CW, et al. Dysregulation of cellular signaling in gastric cancer. Cancer Lett. 2010;295(2):144–53.PubMed CrossRef
121.Kanwar SS, Yu Y, Nautiyal J, et al. The Wnt/beta-catenin pathway regulates growth and maintenance of colonospheres. Mol Cancer. 2010;9:212.PubMed PubMedCentral CrossRef
122.Takahashi-Yanaga F, Kahn M. Targeting Wnt signaling: can we safely eradicate cancer stem cells? Clin Cancer Res. 2010;16(12):3153–62.PubMed CrossRef
123.Cai C, Zhu X. The Wnt/beta-catenin pathway regulates self-renewal of cancer stem-like cells in human gastric cancer. Mol Med Rep. 2012;5(5):1191–6.PubMed
124.Mao J, Fan S, Ma W, et al. Roles of Wnt/beta-catenin signaling in the gastric cancer stem cells proliferation and salinomycin treatment. Cell Death Dis. 2014;5:e1039.PubMed PubMedCentral CrossRef
125.Wang B, Liu J, Ma LN, et al. Chimeric 5/35 adenovirus-mediated Dickkopf-1 overexpression suppressed tumorigenicity of CD44(+) gastric cancer cells via attenuating Wnt signaling. J Gastroenterol. 2013;48(7):798–808.PubMed CrossRef
126.Berman DM, Karhadkar SS, Maitra A, et al. Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature. 2003;425(6960):846–51.PubMed CrossRef
127.Song Z, Yue W, Wei B, et al. Sonic hedgehog pathway is essential for maintenance of cancer stem-like cells in human gastric cancer. PLoS One. 2011;6(3):e17687.PubMed PubMedCentral CrossRef
128.Kim TH, Shivdasani RA. Notch signaling in stomach epithelial stem cell homeostasis. J Exp Med. 2011;208(4):677–88.PubMed PubMedCentral CrossRef
129.Yeh TS, Wu CW, Hsu KW, et al. The activated Notch1 signal pathway is associated with gastric cancer progression through cyclooxygenase-2. Cancer Res. 2009;69(12):5039–48.PubMed CrossRef
130.Brzozowa M, Mielanczyk L, Michalski M, et al. Role of Notch signaling pathway in gastric cancer pathogenesis. Contemp Oncol. 2013;17(1):1–5.
131.Purow B. Notch inhibition as a promising new approach to cancer therapy. Adv Exp Med Biol. 2012;727:305–19.PubMed PubMedCentral CrossRef
132.Botchkina G. Colon cancer stem cells–from basic to clinical application. Cancer Lett. 2013;338(1):127–40.PubMed CrossRef
133.Zhan HX, Xu JW, Wu D, et al. Pancreatic cancer stem cells: new insight into a stubborn disease. Cancer Lett. 2015;357(2):429–37.PubMed CrossRef
134.Carrasco E, Alvarez PJ, Prados J, et al. Cancer stem cells and their implication in breast cancer. Eur J Clin Invest. 2014;44(7):678–87.PubMed CrossRef
135.Jackson M, Hassiotou F, Nowak A. Glioblastoma stem-like cells: at the root of tumor recurrence and a therapeutic target. Carcinogenesis. 2015;36(2):177–85.PubMed CrossRef
136.Lundin A, Driscoll B. Lung cancer stem cells: progress and prospects. Cancer Lett. 2013;338(1):89–93.PubMed PubMedCentral CrossRef
137.Lang D, Mascarenhas JB, Shea CR. Melanocytes, melanocyte stem cells, and melanoma stem cells. Clin Dermatol. 2013;31(2):166–78.PubMed PubMedCentral CrossRef
138.Sharpe B, Beresford M, Bowen R, et al. Searching for prostate cancer stem cells: markers and methods. Stem Cell Rev. 2013;9(5):721–30.PubMed CrossRef
139.Fukamachi H, Shimada S, Ito K, et al. CD133 is a marker of gland-forming cells in gastric tumors and Sox17 is involved in its regulation. Cancer Sci. 2011;102(7):1313–21.PubMed CrossRef
140.Zhu Y, Yu J, Wang S, et al. Overexpression of CD133 enhances chemoresistance to 5-fluorouracil by activating the PI3K/Akt/p70S6K pathway in gastric cancer cells. Oncol Rep. 2014;32(6):2437–44.PubMed
141.Zhi QM, Chen XH, Ji J, et al. Salinomycin can effectively kill ALDH(high) stem-like cells on gastric cancer. Biomed Pharmacother. 2011;65(7):509–15.PubMed CrossRef
142.Yu D, Shin HS, Choi G, et al. Proteomic analysis of CD44(+) and CD44(−) gastric cancer cells. Mol Cell Biochem. 2014;396(1–2):213–20.PubMed CrossRef
143.Hong RL, Lee WJ, Shun CT, et al. Expression of CD44 and its clinical implication in diffuse-type and intestinal-type gastric adenocarcinomas. Oncology. 1995;52(4):334–9.PubMed CrossRef
144.Ghaffarzadehgan K, Jafarzadeh M, Raziee HR, et al. Expression of cell adhesion molecule CD44 in gastric adenocarcinoma and its prognostic importance. World J Gastroenterol. 2008;14(41):6376–81.PubMed PubMedCentral CrossRef
145.Nosrati A, Naghshvar F, Khanari S. Cancer Stem Cell Markers CD44, CD133 in Primary Gastric Adenocarcinoma. Int J Mol Cell Med. 2014;3(4):279–86.PubMed PubMedCentral
146.Lee HH, Seo KJ, An CH, et al. CD133 expression is correlated with chemoresistance and early recurrence of gastric cancer. J Surg Oncol. 2012;106(8):999–1004.PubMed CrossRef
147.Yu JW, Zhang P, Wu JG, et al. Expressions and clinical significances of CD133 protein and CD133 mRNA in primary lesion of gastric adenocacinoma. J Exp Clin Cancer Res. 2010;29:141.PubMed PubMedCentral CrossRef
148.Zhao P, Li Y, Lu Y. Aberrant expression of CD133 protein correlates with Ki-67 expression and is a prognostic marker in gastric adenocarcinoma. BMC Cancer. 2010;10:218.PubMed PubMedCentral CrossRef
149.Hashimoto K, Aoyagi K, Isobe T, et al. Expression of CD133 in the cytoplasm is associated with cancer progression and poor prognosis in gastric cancer. Gastric Cancer. 2014;17(1):97–106.PubMed PubMedCentral CrossRef
150.Jiang Y, He Y, Li H, et al. Expressions of putative cancer stem cell markers ABCB1, ABCG2, and CD133 are correlated with the degree of differentiation of gastric cancer. Gastric Cancer. 2012;15(4):440–50.PubMed CrossRef
151.Muller W, Schneiders A, Heider KH, et al. Expression and prognostic value of the CD44 splicing variants v5 and v6 in gastric cancer. J Pathol. 1997;183(2):222–7.PubMed CrossRef
152.Yamaguchi A, Goi T, Yu J, et al. Expression of CD44v6 in advanced gastric cancer and its relationship to hematogenous metastasis and long-term prognosis. J Surg Oncol. 2002;79(4):230–5.PubMed CrossRef
153.Okayama H, Kumamoto K, Saitou K, et al. CD44v6, MMP-7 and nuclear Cdx2 are significant biomarkers for prediction of lymph node metastasis in primary gastric cancer. Oncol Rep. 2009;22(4):745–55.PubMed
154.Xin Y, Grace A, Gallagher MM, et al. CD44V6 in gastric carcinoma: a marker of tumor progression. Appl Immunohistochem Mol Morphol. 2001;9(2):138–42.PubMed
155.Chen JQ, Zhan WH, He YL, et al. Expression of heparanase gene, CD44v6, MMP-7 and nm23 protein and their relationship with the invasion and metastasis of gastric carcinomas. World J Gastroenterol. 2004;10(6):776–82.PubMed PubMedCentral
156.Kurozumi K, Nishida T, Nakao K, et al. Expression of CD44 variant 6 and lymphatic invasion: importance to lymph node metastasis in gastric cancer. World J Surg. 1998;22(8):853–7 (discussion 7-8).PubMed CrossRef
157.Yasui W, Kudo Y, Naka K, et al. Expression of CD44 containing variant exon 9 (CD44v9) in gastric adenomas and adenocarcinomas: relation to the proliferation and progression. Int J Oncol. 1998;12(6):1253–8.PubMed
158.Go SI, Ko GH, Lee WS, et al. CD44 variant 9 serves as a poor prognostic marker in early gastric cancer, but not in advanced gastric cancer. Can Res Treat. 2015. doi:10.4143/crt.2014.227 .
159.Hirata K, Suzuki H, Imaeda H, et al. CD44 variant 9 expression in primary early gastric cancer as a predictive marker for recurrence. Br J Cancer. 2013;109(2):379–86.PubMed PubMedCentral CrossRef
160.Yong CS, Ou Yang CM, Chou YH, et al. CD44/CD24 expression in recurrent gastric cancer: a retrospective analysis. BMC Gstroenterol. 2012;12:95.CrossRef
161.Cao L, Hu X, Zhang J, Liang P, Zhang Y. CD44(+) CD324(−) expression and prognosis in gastric cancer patients. J Surg Oncol. 2014;110(6):727–33.PubMed CrossRef - 作者单位：Daniel Brungs (1) (2) (3) (4) (5)
Morteza Aghmesheh (1) (3) (4) (5)
Kara L. Vine (1) (2) (4) (5)
Therese M. Becker (4) (5) (6) (7)
Martin G. Carolan (1) (3) (4) (5)
Marie Ranson (1) (2) (4) (5)
1. Illawarra Health and Medical Research Institute, University of Wollongong, Wollongong, 2522, Australia
2. School of Biological Sciences, University of Wollongong, Wollongong, 2522, Australia
3. Illawarra Cancer Centre, Wollongong Hospital, Wollongong, Australia
4. CONCERT-Translational Cancer Research Centre, Sydney, New South Wales, Australia
5. Ingham Institute for Applied Medical Research, Liverpool Hospital, Liverpool, Australia
6. School of Medicine, University of Western Sydney, Liverpool, Australia
7. South Western Medical School, University of New South Wales, Liverpool, Australia - 刊物类别：Medicine
- 刊物主题：Medicine & Public Health
Gastroenterology
Oncology
Surgical Oncology
Hepatology
Internal Medicine
Colorectal Surgery - 出版者：Springer Japan
- ISSN：1435-5922
文摘
Gastric cancer is a significant global health problem. It is the fifth most common cancer and third leading cause of cancer-related death worldwide (Torre et al. in CA Cancer J Clin 65(2):87–108, 2015). Despite advances in treatment, overall prognosis remains poor, due to tumour relapse and metastasis. There is an urgent need for novel therapeutic approaches to improve clinical outcomes in gastric cancer. The cancer stem cell (CSC) model has been proposed to explain the high rate of relapse and subsequent resistance of cancer to current systemic treatments (Vermeulen et al. in Lancet Oncol 13(2):e83–e89, 2012). CSCs have been identified in many solid malignancies, including gastric cancer, and have significant clinical implications, as targeting the CSC population may be essential in preventing the recurrence and spread of a tumour (Dewi et al. in J Gastroenterol 46(10):1145–1157, 2011). This review seeks to summarise the current evidence for CSC in gastric cancer, with an emphasis on candidate CSC markers, clinical implications, and potential therapeutic approaches.